Galileo Acquisition Corp. Files $100 Million SPAC
by Kristi Marvin on 2019-10-02 at 8:09pm

This afternoon, we had yet another new SPAC filing, making the count four (4) for deals on file to IPO.  Furthermore, that means that if all four price in October, we will match 2018’s deal count of 46. It also means we are very, very close to matching the 2018 total gross proceeds figure of $10.752 billion, i.e., if all four price (without over-allotments) SPACs will have raised $10.695 billion in 2019 year-to-date. However, what do we have on deck with today’s new SPAC filing?

For starters, the name is Galileo Acquisition Corp. (GLEO.U), a $100 million SPAC focused on “the consumer, retail, food & beverage, specialty industrial, technology or medtech sectors which are headquartered in Western Europe, with an emphasis on Italian family-owned businesses, portfolio companies of private equity funds, or corporate spin-offs, and that have significant North American exports and a clearly defined North American high growth strategy.”  That’s a real kitchen sink, so for simplicity’s sake, let’s just say “Western Europe/Italy”.

Additionally, Galileo will be led by Luca Giacometti, who has previously been involved with four European-listed SPACs and has the distinction of launching the first blank check company under Italian law in 2011 (Made in Italy).

  • 2017 – Glenalta (merged with CFT S.p.A.)
  • 2015 – Glenalta Food (merged with Orsero S.p.A.),
  • 2014 – IPO Challenger (merged with Italian Wine Brands S.p.A.),
  • 2011 – Made in Italy 1 (merged with SeSa S.p.A.)

Apparently, Italian SPACs are all the rage and even Bob Diamond (the former Barclays chief executive) had one called “SPAXs“. But are Italian SPACs similar to U.S. listed ones? Hard to say.  In the interest of time, I’ve only done a cursory bit of research on Italian SPACs (will be looking more closely soon), but the premise appears to be the same.  It’s the investor base that’s probably going to be quite different though and that is really the crucial thing that matters.  U.S. SPAC investors are a different breed and they can be tough on both on the front end as well as the back end. However, looking at the terms, we see that Galileo is a 21 months (+ 3 months with a definitive agreement), 1 full warrant, 100% in trust SPAC.  It’s a fairly uncomplicated structure, straightforward, and they are looking at a broad swath of sectors within Western Europe and more specifically, Italy.  On the surface, without hearing the team’s pitch, these terms seem sell-able.

More to come after doing a bit more research on Italian SPACs. For now, summary of terms below:

 

Galileo Terms 10-2-19

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved